Republicans drop Trump-ordered block on state AI laws from defense bill

Ars TechnicaWednesday, December 3, 2025 at 9:06:34 PM
PositiveTechnology
Republicans drop Trump-ordered block on state AI laws from defense bill
  • Republicans have decided to remove a block on state-level artificial intelligence (AI) laws that was previously ordered by former President Donald Trump from the defense bill. This decision reflects a significant shift in the party's stance on AI governance, allowing states to implement their own regulations without federal interference.
  • The removal of this block is crucial as it empowers states to establish their own frameworks for AI regulation, which can lead to more tailored and effective governance of emerging technologies. This move may also signal a growing independence within the Republican Party regarding technology policy.
  • This development highlights ongoing tensions within the Republican Party regarding AI regulation, as divisions have emerged over the approach to federal versus state governance. Additionally, the rise of AI as a political tool has seen right-wing factions leverage technology to promote their agendas, indicating a complex interplay between politics and technological advancement.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended apps based on your readingExplore all apps
Continue Readings
Trump's push to overrule AI regulation falters as Republicans split
NegativeTechnology
Former President Donald Trump is facing challenges in his efforts to override state-level regulations on artificial intelligence (AI), as divisions emerge within the Republican Party regarding the approach to AI governance. Trump argues that these regulations are hindering U.S. growth amid increasing competition from China.
More FDA drama: Top drug regulator calls it quits after 3 weeks
NegativeTechnology
The top drug regulator at the FDA has resigned after just three weeks in office, marking the departure of the last Trump administration official in this role amid allegations of petty revenge. This sudden exit raises questions about the stability and leadership within the FDA during a critical time for public health and drug regulation.